ArticleCells2026
Loss of PIK3CA Allows
Abigail L Booth, Giuseppe Caso, Barbara Rosati, Ya-Ping Jiang, Wei-Xing Zong, Richard Z Lin, Harold Bien
Abstract read
In one paragraphArticle in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
7 authors.
Abigail L BoothDepartment of Physiology & Biophysics, Stony Brook University, Stony Brook, NY 11794, USA.
Giuseppe CasoDepartment of Physiology & Biophysics, Stony Brook University, Stony Brook, NY 11794, USA.
Barbara RosatiDepartment of Physiology & Biophysics, Stony Brook University, Stony Brook, NY 11794, USA.
Ya-Ping JiangDepartment of Physiology & Biophysics, Stony Brook University, Stony Brook, NY 11794, USA.
Wei-Xing ZongDepartment of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey, Piscataway, NJ 08854, USA.ORCID 0000-0002-3129-8220 Richard Z LinDepartment of Physiology & Biophysics, Stony Brook University, Stony Brook, NY 11794, USA.
Funding
PIK3CA signaling and pancreatic cancerR21CA274425 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI LIN, RICHARD Z · 2023 to 2024
$395kBLRD VA I01 BX006313LUNGevity Foundation 2021-06NCI NIH HHS R21CA274425Stony Brook Medicine Dec-2021United States Department of Veteran Affairs 1I01BX006313United States Department of Veteran Affairs I50CU000162
6 · The paper itselfAbstract
Constitutively active KRAS mutations are highly prevalent in lung cancers, but the direct role of its downstream phosphatidylinositol 3-kinase (PI3K) pathway in tumor progression remains unclear. A previous study established the requirement for PIK3CA, the alpha catalytic isoform, in lung tumor development in mouse models with an intact
Indexed as
Adenocarcinoma of LungClass I Phosphatidylinositol 3-KinasesLung NeoplasmsMutationProto-Oncogene Proteins p21(ras)AMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsCell Line, TumorCell ProliferationDisease Models, AnimalDisease ProgressionHumansMiceProtein Serine-Threonine KinasesTumor Suppressor Protein p53AMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesClass I Phosphatidylinositol 3-KinasesHras protein, mousePik3ca protein, mouseProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)Stk11 protein, mouseTumor Suppressor Protein p53KRASLUADlung cancerorthotopic modelPIK3CASTK11
Identifiers
PMID41892297
PMCPMC13025534
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390